2023
Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us
Galderisi A. Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us. Pediatric Endocrinology Diabetes And Metabolism 2023, 29: 1-3. PMID: 37218722, PMCID: PMC10226454, DOI: 10.5114/pedm.2023.126360.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBeta-cell functionType 1 diabetesIslet autoimmunityCell functionFunctional beta-cell massDisease-modifier drugsUnderlying autoimmune processPre-symptomatic phaseBeta-cell massSymptomatic diabetesAutoimmune processClinical onsetSurrogate markerDiabetes progressionC-peptideInsulin secretionModifier drugsEarly changesDiabetesMetabolic changesDysglycaemiaAutoimmunityT1DOnsetModifier treatment
2019
A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes.
Galderisi A, Sherr JL. A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes. Pediatric Annals 2019, 48: e311-e318. PMID: 31426099, DOI: 10.3928/19382359-20190725-03.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsContinuous glucose monitoringType 1 diabetesGlycemic controlContinuous subcutaneous insulin infusion pumpClosed-loop insulin deliveryIntensive insulin treatmentMultiple daily injectionsChronic medical conditionsLoop insulin deliveryPediatric clinical practiceInsulin infusion pumpDaily injectionsBlood glucoseInsulin treatmentMedical conditionsDiabetes treatmentClinical practiceNew treatmentsGlucose monitoringInfusion pumpInsulin deliveryT1DDiabetesTreatmentSuspension device1054-P: Insulin Sensitivity from Sensor and Pump Data in Youths with Type 1 Diabetes: Hybrid Closed-Loop Validation
SCHIAVON M, GALDERISI A, KRAEMER K, COBELLI C, MAN C, CENGIZ E. 1054-P: Insulin Sensitivity from Sensor and Pump Data in Youths with Type 1 Diabetes: Hybrid Closed-Loop Validation. Diabetes 2019, 68 DOI: 10.2337/db19-1054-p.Peer-Reviewed Original ResearchContinuous glucose monitoringInsulin sensitivityType 1 diabetesEuropean Medical Information FrameworkInsulin pump dataClosed-loop treatmentOral minimal modelMannKind CorporationSequential mealsInsulin therapyMeal studyPlasma glucoseGlycemic outcomesType 1Glucose monitoringSpeakers bureauMeal variationT1D.T1DInternational SocietyAdvisory PanelPump dataTreatmentSI indexDiabetes
2017
Metabolomics reveals new metabolic perturbations in children with type 1 diabetes
Galderisi A, Pirillo P, Moret V, Stocchero M, Gucciardi A, Perilongo G, Moretti C, Monciotti C, Giordano G, Baraldi E. Metabolomics reveals new metabolic perturbations in children with type 1 diabetes. Pediatric Diabetes 2017, 19: 59-67. PMID: 28401628, DOI: 10.1111/pedi.12524.Peer-Reviewed Original ResearchConceptsBody mass indexType 1 diabetesHealthy controlsPubertal statusExcess of cortisolMetabolome of childrenPediatric diabetes clinicMacrovascular complicationsDiabetes clinicDisease durationNeuronal damagePediatric patientsClinical featuresMass indexCase groupTryptophan catabolitesHealthy peersUrinary metabolitesUrinary samplesBacterial productsT1DUntargeted metabolomics approachMetabolic perturbationsDiabetesPatients
2015
Cardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes
Lipes M, Galderisi A. Cardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes. Current Diabetes Reports 2015, 15: 30. PMID: 25821130, PMCID: PMC4376963, DOI: 10.1007/s11892-015-0598-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular diseaseHeart diseaseChronic myocardial inflammationPoor CVD outcomesUnderstanding of CVDType 1 diabetesCardiac autoimmunityMicrovascular complicationsCVD outcomesMyocardial inflammationClinical evidenceHeart syndromeExcess mortalityClinical studiesNovel biomarkersT1DTherapeutic implicationsTherapeutic targetType 2Type 1Same diseaseT2D.DiseaseDiagnostic assaysT1D.